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Molecular biological studies have recently revealed that various
molecules including cyclins, cyclin-dependent kinases (CDKs)
and CDK inhibitors (CDKIs) play important roles in controlling
major checkpoints in the mammalian cell cycle. At least nine
classes of cyclins and seven CDKs, including G1 cyclins (D1–3,
E and A) and their catalytic partners, CDKs (2, 4 and 6), have now
been isolated (Sherr, 1993, 1994; Nakamura et al, 1995; Weinberg
et al, 1995). CDK4 and CDK6 are activated by formation of a
complex with D-type cyclins which acts as a growth sensor,
phosphorylates, and inactivates pRB, the product of the retinoblas-
toma tumour suppressor gene (Sherr, 1994). Unphosphorylated
pRB binds to and inactivates transcription factors including E2F,
and prevents the G1–S transition, whereas phosphorylated pRB
prevents the interaction of pRB with E2F and enables it to promote
gene expression (Weinberg et al, 1995). CDK2 binds to cyclin E or
cyclin A, and also inactivates pRB and regulates G1–S phase
(Sherr, 1994; Weinberg et al, 1995). On the other hand, CDKs are
negatively regulated by the CIP/KIP family of CDKIs including
p21, p27 and p57, and by INK4 proteins including p15, p16, p18
and p19 (Sherr, 1996). The CIP/KIP family combines with the
cyclin–CDK complex and inactivates it, whereas INK4 proteins
directly form complexes with CDK4 and CDK6 and inactivate
them and regulate G1 progression (Sherr, 1994, 1996; Lee et al,
1995; Weinberg et al, 1995).
Recently, alteration of the genes encoding these cell cycle regu-
lators have, along with oncogenes and tumour suppressor genes,
been reported to contribute to oncogenesis (Sherr, 1996). In
various human tumours, aberrant expressions of these cyclins,
CDKs, and CDKIs have been reported, and it has been suggested
that the loss of cell cycle regulation due to dysregulated expression
of these proteins, especially those in the CDK4/cyclin D1-pRB
pathway, directly contributes to tumorigenesis (Motokura et al,
1993; Bartkova et al, 1996; Sherr, 1996).
Previous studies of human oesophageal squamous cell carci-
noma (SCC) have presented evidence of overexpression of cyclin
D1 at the DNA, mRNA or protein level in addition to altered
expression of pRB, p53 (Jiang et al, 1993; Tsuruta et al, 1993;
Igaki et al, 1994; Wang et al, 1994; Naitoh et al, 1995). It has been
also reported that there was a good relationship between cyclin D1
protein expression and gene amplification (Sheyn et al, 1997).
Our findings have also demonstrated a relationship between the
expression of cyclins, especially cyclin D1 and cyclin E, and
various clinicopathological factors relevant to patient prognosis
(Furihata et al, 1996; Ishikawa et al, 1998). In addition, both of the
tumour suppressor genes, p53 and pRB, appeared to be involved in
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Summary The expressions of cyclin D1, cyclin E, cyclin-dependent kinase 4 (CDK4), and CDK2 were immunohistochemically examined in
90 patients with human oesophageal squamous cell carcinoma (SCC) to determine their relationship to the tumour behaviour and patient
prognosis. Nuclear immunostaining of cyclin D1 and cyclin E was observed in 28 (31.1%) and 27 tumours (30.0%) respectively. Thirty-nine
tumours (43.3%) and 31 tumours (34.4%) exhibited both cytoplasmic and nuclear positivity for CDK4 and CDK2 respectively. Of 28 cyclin
D1-positive and 27 cyclin E-positive tumours, CDK4 was overexpressed in 12 (42.8%) tumours and CDK2 in seven (25.9%) tumours
respectively. There was no significant relationship in immunopositivity between cyclin D1 and CDK4 or between cyclin E and CDK2.
Simultaneous immunoreactivity for both cyclin D1 and CDK4 was significantly associated with venous invasion (P < 0.05). In a univariate
analysis, the prognosis of patients with tumours that were both cyclin D1- and CDK4-positive was significantly poorer than that of patients with
cyclin D1-negative tumours (P < 0.05). In a multivariate analysis, both cyclin D1 and CDK4 immunoreactivities (P < 0.01) and tumour stage
(P < 0.001) were recognized as independent risk factors. In this analysis, the hazard ratio for cyclin D1-positive and CDK4-negative cases
compared with cyclin D1-negative cases was significant (hazard ratio = 3.128, 95% confidence interval = 1.418–6.899, P = 0.0047). No
significant prognostic relevance was detected in both cyclin E and CDK2 immunoreactivity. Our in vivo findings suggest that in human
oesophageal SCC, cyclin D1 and cyclin E and their functional partners, CDK4 and CDK2, often exhibit dysregulated overexpression in many
cases, and that tumours with simultaneous expression of cyclin D1 and CDK4 are frequently associated with venous invasion and have a
worse prognosis, statistically. Moreover, overexpression of cyclin D1 alone may also contribute to tumour progression independent of CDK4
overexpression.
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Although CDK4, cyclin E and CDK2 are thought to play impor-
tant roles in tumorigenesis (Khatib et al, 1993; Marone et al,
1998), no detailed studies have been performed including the
immunohistochemical detection and prognostic relevance of these
proteins in human oesophageal SCC.
In this study, we immunohistochemically examined 90 cases of
human oesophageal SCC to elucidate the immunoreactive correla-
tion between cyclin D1 and CDK4 or cyclin E and CDK2, the
possible roles of these proteins in tumour development and their
effects on patient prognosis. The relationships of overexpression
of these proteins with various clinicopathological factors were
then tested, statistically.
MATERIALS AND METHODS
Patients and tumour samples
Ninety cases of primary human oesophageal SCC consecutively
obtained at oesophagectomy in the Department of Surgery II,
Kochi Medical School between 1982 and 1997 were studied.
All patients had received mild chemotherapy with bleomycin
(20 mg m–2) per day as an oral administration over 5 days, but no
radiation therapy prior to surgery. All patients were followed in
Kochi Medical School and 23 out of 90 patients received
chemotherapy with 5-fluorouracil (5-FU) (1600 mg m–2) and
CDDP (70 mg m–2) as an intravenous infusion over 10 days due to
the recurrence. Of the patients, 79 (87.8%) were male and 11
(12.2%) were female. The mean age was 62.2 years (range 41–86
years). In all cases, histological or clinical classification was made
using the Guidelines for Clinical and Pathological Studies on
Carcinoma of the Esophagus established by the Japanese Society
for Esophageal Disease (1992). Tumour specimens were fixed in
10% buffered formalin, processed routinely and embedded in
paraffin. In each case, all available haematoxylin and eosin-stained
sections were reviewed, and a representative block was chosen for
further studies.
Immunohistochemistry with cyclin D1, cyclin E, CDK4
and CDK2 antibodies
Five micrometer-thick sections from archival formalin-fixed
paraffin-embedded tissues were placed on poly-L-lysine-coated
slides (Sigma Chemical Co., St Louis, MO, USA) for immuno-
histochemistry (IHC). The expressions of cyclin D1, cyclin E,
CDK4 and CDK2 were assessed by immunohistochemical exami-
nation using an anti-human cyclin D1 monoclonal antibody
(P2D11F11, dilution 1:50; Novocastra, Newcastle, UK), an anti-
human cyclin E monoclonal antibody (13A3, dilution 1:50;
Novocastra, Newcastle, UK), an anti-human CDK4 polyclonal
antibody (dilution 1:500; Pharmingen, San Diego, CA, USA) and
an anti-human CDK2 polyclonal antibody (dilution 1:500; Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA) respectively.
After blocking of endogenous peroxidase activity, the sections
were autoclaved in 10 mM citrate buffer for 12 min at 132°C for
antigen retrieval. The deparaffinized sections were pre-treated
with normal goat serum for 30 min and incubated with each anti-
body at 4°C overnight. Immunohistochemical staining for these
proteins was then performed using the avidin–biotin complex
procedure with a streptavidin–biotin complex peroxidase kit
(Histofine SAB-PO Kit; Nichirei Inc., Tokyo, Japan).
The sections were scanned by the two pathologists (MF and
YO) simultaneously using a double-headed microscope to identify
the areas that were most evenly stained. In each case, 200–500
tumour cells were counted and the percentage of immunoreactivity
was determined independently by them. In agreement with a
previous study (Ishikawa et al, 1998), immunostaining of cyclin
D1 and cyclin E was considered positive if the chromogen was
detected in more than 5% of all cancer cells examined. In positive
cases, each score was ranked as: 1+, 5–50 positive; or 2+, more
than 50% positive.
CDK4 and CDK2 immunoreactivities were observed in both
nuclei and cytoplasm of cancer cells and were confined to the
basal and parabasal cell layers of non-neoplastic oesophageal
epithelium, inflammatory cells, fibroblasts, muscle cells and
endothelial cells. This staining was regarded as an internal positive
control for immune reaction. Since no study of immunostaining
for CDK4 and CDK2 in human oesophageal SCC had previously
been performed, we used the same scoring method as their part-
ners, cyclin D1 and cyclin E, described above.
Statistical analysis
The correlations between cyclin D1 and CDK4 or cyclin E and
CDK2 expression as well as the overexpression of these proteins
relevant to the various clinicopathological factors were determined
using the c2 test (P < 0.05).
Association between cyclin D1 and CDK4 or cyclin E
and CDK2 overexpression and prognosis
The cumulative survival rates were calculated by the Kaplan–
Meier method and the statistical significance of differences was
determined using the log-rank test (P < 0.05) (with time to death as
end-point). A Cox proportional hazards model for risk ratio was
also used to assess the simultaneous contributions of cyclins and
CDKs immunoreactivities and clinicopathological factors to
patient survival.
RESULTS
Immunohistochemistry with cyclin D1, cyclin E, CDK4
and CDK2 antibodies
We immunohistochemically examined the expression of cyclin
D1, cyclin E, CDK4 and CDK2 in 90 cases of human oesophageal
SCC. In total, 28 of 90 (31.1%) tumours exhibited positive
staining with cyclin D1-antibody, including five (5.6%) cases of
2+ staining and 23 (25.5%) of 1+ staining. Twenty-seven of the 90
tumours (30.0%), including five (5.6%) cases of 2+ staining and
22 (24.4%) cases of 1+ staining, were positive for cyclin E-anti-
body. Staining of both cyclin D1 and cyclin E was principally
observed in the nucleus of tumour cells. Focal and weak staining
of cyclin D1 and cyclin E was observed in normal mucosa adjacent
to tumours, but was always restricted to the parabasal cell layer of
non-cancerous squamous cell epithelium. Thirty-nine of the 90
tumours (43.3%), including 15 (16.7%) cases of 2+ staining and
24 (26.6%) cases of 1+ staining, and 31 of 90 tumours (34.4%),
including five (5.6%) cases of 2+ staining and 26 (28.8%) cases of
1+ staining, were positive in both cytoplasm and nucleus for
CDK4 (Figure 1) and CDK2 antibodies respectively. Focal and
weak nuclear positive staining of CDK4 (Figure 1) and CDK2 was
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observed in the basal and parabasal cell layers of normal
oesophageal epithelium.
Of cyclin D1- and cyclin E-positive cases, respectively, 12
(42.9%) of 28 and seven (25.9%) of 27 tumours were positive for
CDK4 and CDK2, but the remaining 16 (57.1%) and 20 (74.1%)
tumours failed to exhibit CDK4 (Figure 2) or CDK2 immuno-
reactivity.
Statistical analysis
Statistical analysis was performed using the c2 test to determine
the correlations of immunoreactivities for cyclin D1 and CDK4,
and for cyclin E and CDK2. The results, as shown in Table 1 (a and
b), failed to demonstrate a significant relationship among these
protein expressions in immunoreactivity.
Figure 1 CDK4 immunoreactivity of oesophageal SCC and non-neoplastic
oesophageal epithelium adjacent to tumours. Both cytoplasmic and nuclear
immunostainings were observed in cancer cells. Focal and weak nuclear
immunopositivity was seen in parabasal layer of non-neoplastic oesophageal
epithelium. Reactive follicles and inflammatory infiltrates were also positive
A
B
Figure 2 Cyclin D1 immunopositivity, revealing nuclear predominancy in a
case (A), but CDK4 (B) was negative in the identical case
Table 1 Correlation of cyclin D1 and CDK4 (a), or cyclin E and CDK2
protein expression (b) in esophageal squamous cell carcinoma
Cyclin D1
a Positive Negative P-value
(1+, 2+) (–)
Positive 12 27
(1+, 2+)
CDK4 >0.1
Negative 16 35
(–)
Cyclin E
b Positive Negative P-value
(1+,2+) (–)
Positive 7 24
(1+,2+)
CDK2 >0.1
Negative 20 39
(–)
Table 2 Summary of the relationship between the cyclin D1 and CDK4
immunoreactivity and clinicopathological factors in 90 cases of oesophageal
SCC
Group I Group II Group III Total
(12 cases) (16 cases) (62 cases) (90 cases)
Age
<60 4 11 22 37
60–70 6 2 25 33
>70 2 3 15 20
Sex
Male 10 15 54 79
Female 2 1 8 11
Histological type
Well 5 2 16 23
Moderately 6 9 40 55
Poor 1 5 6 12
Venous invasion (P < 0.05)
(+) 10 5 25 40
(–) 2 11 37 50
Lymphatic invasion
(+) 12 11 42 65
(–) 0 5 20 25
Lymphnode metastasis
(+) 7 7 29 43
(–) 5 9 33 47
Stage
0,I 1 9 23 33
II 3 2 11 16
III 7 3 14 24
IV 1 2 14 17
Group I: both cyclin D1- and CDK4-positive cases; group II: cyclin
D1-positive and CDK4-negative cases; group III: cyclin D1-negative cases.Cyclins and CDKs in oesophageal SCC 259
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In addition, we divided the 90 patients into three groups based
on cyclin D1 and CDK4 immunoreactivity, i.e. cases positive for
both cyclin D1 and CDK4 (group I), cases positive for cyclin D1
but negative for CDK4 (group II) and cases negative for cyclin D1
(group III), and investigated the relationship among these three
groups and various clinocopathological factors such as patient age,
sex, tumour histological type, vascular and lymphatic invasion,
lymph node status and stage. The results, as summarized in Table
2, revealed a significant relationship only between group I and
venous invasion (P < 0.05). No significant relationship was found
between any group and any other clinicopathological parameter.
We performed the same type of analysis using the results of
staining for cyclin E and CDK2, but no significant relationship
was found between any group and any clinicopathological para-
meter.
No significant relationship in immunoreactivities of any
proteins tested between the cases with and without post-operative
chemotherapy was detected.
Association between cyclin D1 and CDK4 or cyclin E
and CDK2 overexpression related to patient prognosis
The cumulative survival curves for patients with oesophageal SCC
are shown in Figure 3. The outcome of patients with tumours
exhibiting simultaneous expression of both cyclin D1 and CDK4
(group I) was significantly poorer than that of patients with cyclin
D1-negative tumours (group III) (P < 0.05), while no significant
difference in outcome was observed between group I and group II.
On the other hand, cyclin E and CDK2 overexpressions were unre-
lated to survivals (data not shown). No prognostic relationship
between the patients with and without post-operative chemotherapy
was detected.
To determine the effects of predictor variables which were
recognized as significant prognostic factors by univariate analysis,
including venous invasion, lymphatic invasion, lymph node status,
tumour stage and simultaneous immunoreactivity for both cyclin
D1 and CDK4, we performed a multivariate analysis using the
Cox stepwise proportional hazard model. In this analysis, both
cyclin D1 and CDK4 immunoreactivities (P < 0.01) and tumour
stage (P < 0.001) were recognized as independent prognostic
factors (Table 3), while other predictors did not retain a significant
effect on survival. In addition, group II had poorer survival than
group III with a significant hazard ratio of 3.128 (95% confidence
interval (CI) = 1.418–6.899, P = 0.0047), which was larger than
that in group 1 versus group III (hazard ratio (HR) = 2.418, 95%
CI = 1.028–5.686, P = 0.043) (Table 3).
DISCUSSION
We studied the overexpression of cyclin D1, cyclin E, CDK4 and
CDK2 proteins in 90 patients with oesophageal SCC, and assessed
the relationships in immunoreactivities between cyclin D1 and
CDK4, and between cyclin E and CDK2. The relationships
between immunopositivity for these proteins and various clinico-
pathological features and patient prognosis were also statistically
examined. Immunohistochemistry using antibodies to cyclin D1,
cyclin E, CDK4 and CDK2 made possible precise measurement of
the rates of cyclin D1, cyclin E, CDK4 and CDK2 expressions
with their patterns of expression in individual tumours, and may be
a suitable method for screening of abnormal expression of cyclin
D1, cyclin E, CDK4 and CDK2.
The present study revealed that a total of 32.2% (29/90) and
30.0% (27/90) of tumour samples exhibited increased expression
of cyclin D1 and cyclin E protein respectively. This expression
was observed principally in the nuclei of cancer cells, while
totals of 44.4% (40/90) and 35.6% (32/90) of tumour samples
exhibited increased expression of CDK4 and CDK2 proteins,
respectively, with both cytoplasmic and nuclear immunopositivity.
Interestingly, 12 (42.9%) of 28 cyclin D1-positive tumours and
seven (25.9%) of 27 cyclin E-positive tumours co-overexpressed
their functional partners, CDK4 and CDK2. Furthermore, as
expected for these given immunoreactivities, statistical analysis
also revealed no significant relationship between cyclin D1 and
CDK4 or cyclin E and CDK2 overexpression. A previous study
found a significant correlation in mRNA levels between cyclin
D1 and CDK4, and between cyclin E and CDK2, in ovarian carci-
nomas (Masciullo et al, 1997; Marone et al, 1998). Moreover, in
human oesophageal cancer cell lines, a significant association
between the levels of expression of cyclin D1 protein and in vitro
CDK4 enzyme activity has been reported (Doki et al, 1997).
On the other hand, there have been a number of recent reports
of expression of cyclins and CDKs, including cyclin D1, cyclin E,
CDK4 and CDK2, in human malignant tumour cell lines at the
DNA, RNA, or protein level (Dirks et al, 1997; Tominaga et al,
1997). The authors of one of these reports commented that
variation in expression patterns of these proteins may reflect
differences in the biological characteristics of cancer cells and in
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Figure 3 Cumulative Kaplan–Meier survival curves for patients with
oesophageal SCC divided into three groups, i.e. both cyclin D1- and CDK4-
positive cases (group I), cyclin D1-positive and CDK4-negative cases (group
II), and cyclin D1-negative cases (group III)
Table 3 Multivariate analysis of prognostic factors by survivals using Cox
proportional hazard regression model
Value Hazard ratio (95% confidence interval) P-value
Cyclin D1 and CDK4
immunoreactivity 0.0088
Group I/Group III 2.418 (1.028–5.686) 0.0430
Group II/Group III 3.128 (1.418–6.889) 0.0047
Stage <0.0001
I/0 11.298 (2.510–50.843) 0.0016
II/0 7.957 (2.442–25.928) 0.0006
III/0 10.842 (3.491–33.673) <0.0001
IV/0 19.964 (6.169–64.603) <0.0001
Group I: both cyclin D1- and CDK4-positive cases; group II: cyclin D1-
positive and CDK4-negative cases; group III: cyclin D1-negative cases.260 M Matsumoto et al
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the genetic backgrounds acquired during the process of malignant
transformation (Tominaga et al, 1997). Our in vivo findings
suggest that, although CDKs are catalytic partners of cyclins, in
human oesophageal SCC these proteins often exhibit dysregulated
overexpression.
We have recently shown that cyclin D1 overexpression is a
prognostic marker for human oesophageal SCC (Ishikawa et al,
1997). In the present study, we divided cyclin D1-positive cases
into two groups based on immunoreactivity for CDK4, the func-
tional partner of cyclin D1, and evaluated their effects on survival
of patients with oesophageal SCC. We found that the patients with
the tumours exhibiting simultaneous expression of both cyclin D1
and CDK4 had a poorer prognosis than those with cyclin D1-nega-
tive tumours. It has also been reported that abnormal up-regulation
of cyclin D1 and CDK4 contributes to malignant progression
(Zhang et al, 1997). Our findings also suggest that in human
oesophageal SCC, overexpressed cyclin D1 protein promotes
the cell cycle progression together with CDK4 in the cyclin
D1/CDK4-pRB pathway and contributes to tumour progression. In
addition, in a multivariate analysis, patients with cyclin D1-posi-
tive and CDK4-negative tumours were found to have a signifi-
cantly poorer prognosis than those with cyclin D1-negative
tumours. Previous studies have shown that overexpression of
cyclin D1 protein enhances gene amplification (Asano et al, 1995;
Zhou et al, 1996), and that cyclin D1 itself activates oestrogen
receptor transcription independent of CDK4 (Neuman et al, 1997;
Zwijsen et al, 1997). These studies supported an additional role for
cyclin D1 protein independent of the CDK4/cyclin D1-pRB
pathway in tumour progression. Therefore, our results also suggest
that overexpressed cyclin D1 alone may contribute to tumour
progression independent of CDK4 co-expression in oesophageal
SCC. In this study, patients underwent mild chemotherapy pre-
operatively. We think that cytotoxic agents such as bleomycin
might affect the cell cycle. However, all patients were treated iden-
tically pre-operatively, so we think chemotherapy alone had little
effect on the differences in patients, prognosis. In addition, some
patients received post-operative chemotherapy due to recurrence.
However, no prognostic relationship between the patients with and
without post-operative chemotherapy was detected. Therefore we
consider that chemotherapy does not affect our results.
Although the molecular basis for positive immunostaining for
cyclin D1, cyclin E, CDK4 and CDK2 remains under investiga-
tion, this is the first immunohistochemical study to demonstrate
the correlation between these protein expression and clinicopatho-
logical factors, and between their immunoreactivities and patients,
prognosis in human oesophageal SCC. The present findings
suggest that the combinations of cyclin D1 and CDK4, and of
cyclin E and CDK2, are immunohistochemically disorder-over-
expressed in many cases at the protein level, that simultaneous
overexpression of cyclin D1 and CDK4 plays an important role in
tumour progression, and that the overexpression of cyclin D1 itself
also contributes to tumour progression independent of CDK4
overexpression. More comprehensive studies involving greater
numbers of tumours including analyses at the DNA and/or RNA
levels will be needed, and examination of CDKIs will also be
required to confirm the present findings.
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